By the end of this presentation, participants will be able to describe the relative treatment retention rates for first episode opioid replacement treatment between methadone and buprenorphine/naloxone for patients receiving daily witnessed dispensed medications in naturalistic setting. Participants will also be able to list the benefits and risk of different medications used in opioid addictions.
This study is a longitudinal retrospective descriptive study analyzing secondary data from Canada on 1867 patients 18 years of age and older who started first episode opioid agonist therapy with methadone or buprenorphine/naloxone for opioid use disorder during a 4-year period. Treatment episode was defined as date of initial opioid agonist prescription until there is a gap of greater than 6 days without receiving opioid agonist medication at a pharmacy.
Dr. Joseph Sadek, MD, MBA, B.Sc. Pharm, FRCPC, DABPN is an Associate Professor of Psychiatry at Dalhousie University, the clinical and academic leader, NSH acute care and the director of the Atlantic ADHD center in NS.
He served as the VP of CADDRA and currently a member of CADDRA advisory board.
Dr. Sadek is the chair of the Education committee of the Canadian Psychiatric Association and the chair of the senate Appeal Subcommittee of Dalhousie University.
He completed his psychiatry residency training at Dalhousie University in 2004 and his psychopharmacology research training and GCSRT at Harvard University.
Dr.Sadek is the author of 5 books “Clinician’s Guide to ADH (2013), Adult ADHD comorbidities” (Springer, 2016) and child and Adolescents ADHD comorbidities” (2018), Suicide Risk Assessment (2019) and Clinician’s Guide to psychopharmacology (2021). Dr. Sadek received several awards and grants. Latest from the Government of NS House of Assembly in 2019.
He served as the provincial chair the Nova Scotia Suicide Prevention Initiative and member of the provincial education and training committee.
Dr. Sadek is internationally recognized for his expertise in diagnosis and management of mental disorders including ADHD.